IL300151A - Combinations for cancer treatment - Google Patents

Combinations for cancer treatment

Info

Publication number
IL300151A
IL300151A IL300151A IL30015123A IL300151A IL 300151 A IL300151 A IL 300151A IL 300151 A IL300151 A IL 300151A IL 30015123 A IL30015123 A IL 30015123A IL 300151 A IL300151 A IL 300151A
Authority
IL
Israel
Prior art keywords
treatment
cancer
pharmaceutically acceptable
combinations
subject
Prior art date
Application number
IL300151A
Other languages
English (en)
Hebrew (he)
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of IL300151A publication Critical patent/IL300151A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL300151A 2020-07-31 2021-07-29 Combinations for cancer treatment IL300151A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063059601P 2020-07-31 2020-07-31
US202063113556P 2020-11-13 2020-11-13
US202163148921P 2021-02-12 2021-02-12
PCT/US2021/043699 WO2022026706A1 (en) 2020-07-31 2021-07-29 Combinations for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL300151A true IL300151A (en) 2023-03-01

Family

ID=77431400

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300151A IL300151A (en) 2020-07-31 2021-07-29 Combinations for cancer treatment

Country Status (18)

Country Link
US (1) US20230301979A1 (enExample)
EP (1) EP4188376A1 (enExample)
JP (1) JP7847576B2 (enExample)
KR (1) KR20230059792A (enExample)
CN (1) CN116437954A (enExample)
AU (1) AU2021318134A1 (enExample)
BR (1) BR112023001792A2 (enExample)
CA (1) CA3186517A1 (enExample)
CL (1) CL2023000289A1 (enExample)
CO (1) CO2023001561A2 (enExample)
CR (1) CR20230052A (enExample)
GE (1) GEAP202616896A (enExample)
IL (1) IL300151A (enExample)
MX (1) MX2023001298A (enExample)
PE (1) PE20231369A1 (enExample)
PH (1) PH12023550160A1 (enExample)
TW (1) TW202220654A (enExample)
WO (1) WO2022026706A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEAP202415420A (en) * 2018-01-26 2024-12-25 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
KR20220163940A (ko) 2020-02-04 2022-12-12 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 항-디니트로페놀 키메라 항원 수용체
US20230326575A1 (en) * 2020-04-29 2023-10-12 Societe Des Produits Nestle S.A. System and method for providing fertility enhancing dietary recommendations in individuals with low testosterone
WO2021219579A1 (en) * 2020-04-29 2021-11-04 Société des Produits Nestlé S.A. System and method for providing fertility enhancing dietary recommendations in individuals with sperm conditions
JP2025509343A (ja) * 2022-03-07 2025-04-11 サノフィ－アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の治療のための他の薬剤と組み合わせたイサツキシマブの使用
EP4504264A4 (en) * 2022-04-08 2026-03-11 Global Cancer Tech Inc METHODS AND PRODUCTS FOR SCREENING AND TREATMENT OF GLIOBLASTOMA MULTIFORME AND OTHER CANCERS, INCLUDING BREAST CANCERS, USING A COMBINATION OF PI3KINASE INHIBITORS WITH CHECKPOINT INHIBITORS
CN120390641A (zh) * 2022-10-19 2025-07-29 西雅图儿童医院（Dba西雅图儿童研究所） 采用靶向小分子和抗靶向car t细胞的治疗方法
EP4665766A2 (en) * 2023-02-13 2025-12-24 LAVA Therapeutics N.V. Combination therapy comprising multispecific gamma delta tcr antibodies
EP4450972A1 (en) * 2023-04-21 2024-10-23 Fundación Instituto de Investigación Sanitaria de Santiago de Compostela In vitro method for predicting cancer patient response to pd-1 and/or pd-l1 inhibitors
CN117285533B (zh) * 2023-11-24 2024-01-30 四川省医学科学院·四川省人民医院 CD47/SIRPα小分子抑制剂及其应用和抗肿瘤药物组合物
KR20260016691A (ko) * 2024-07-25 2026-02-04 서울대학교산학협력단 Tpst2 억제제 또는 ifngr1의 황산화 억제제를 포함하는 암의 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
JP2019529476A (ja) * 2016-09-27 2019-10-17 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｎ−（４−（６，７−ジメトキシキノリン−４−イルオキシ）フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドを用いた尿路上皮癌及び他の尿生殖器悪性腫瘍の治療方法
BR112019015011A2 (pt) * 2017-01-20 2020-04-28 Exelixis Inc combinações de cabozantinibe e atezolizumabe para tratar câncer
GEAP202415420A (en) * 2018-01-26 2024-12-25 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
EP4631505A3 (en) * 2018-12-13 2025-12-10 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor

Also Published As

Publication number Publication date
WO2022026706A1 (en) 2022-02-03
US20230301979A1 (en) 2023-09-28
MX2023001298A (es) 2023-02-22
PH12023550160A1 (en) 2023-09-18
CL2023000289A1 (es) 2023-09-01
BR112023001792A2 (pt) 2023-04-11
CO2023001561A2 (es) 2023-02-16
CA3186517A1 (en) 2022-02-03
JP2023536264A (ja) 2023-08-24
JP7847576B2 (ja) 2026-04-17
AU2021318134A1 (en) 2023-03-02
TW202220654A (zh) 2022-06-01
KR20230059792A (ko) 2023-05-03
CR20230052A (es) 2023-04-11
EP4188376A1 (en) 2023-06-07
GEAP202616896A (en) 2026-04-27
CN116437954A (zh) 2023-07-14
PE20231369A1 (es) 2023-09-07

Similar Documents

Publication Publication Date Title
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
FI3849534T3 (fi) Yhdistelmähoidot
RU2016130056A (ru) Способы лечения кожной инфекции путем введения антагониста il-4r
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
CA2442168A1 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
RU2010142456A (ru) Синергические комбинации 5'-метилтиоаденозина
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
SV2002000036A (es) Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
IL310115A (en) Treatment of his hyporesponders
JP2019534251A5 (enExample)
IL320024A (en) Perk inhibitor hc-5404 in combination with anti-pd-1 antibody and/or an antiangiogenetic agent for use in the treatment of cancer
CA2476939A1 (en) Pharmaceutical combinations of cox-2 inhibitors and opiates
RU99119233A (ru) Фармацевтические композиции, содержащие ибупрофен и домперидон для лечения мигрени
WO2002064214A8 (en) Anti cancer combination of substituted pyrroles and paclitaxel
CA2595363A1 (en) Methods and materials with trans-clomiphene for the treatment of male infertility
CA2519789A1 (en) Aplidine for multiple myeloma treatment
EP1847274A1 (en) Association of phenylbutyrate, ATRA and cytidine and its use in anti-tumour therapy
JP2019535830A5 (enExample)
CA2633077A1 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
WO2024016000A3 (en) Eif4a inhibitors and uses thereof
MX2025010543A (es) Composiciones que comprenden 5-metoxi-2-aminoindan para el tratamiento de la depresion
CA2469702A1 (en) Darifenacin for use in the treatment of urgency induced by overactive bladder
MX2026000880A (es) Sales, cocristales, composiciones farmaceuticas de los mismos, y metodos de tratamiento que implican los mismos
TW202617147A (zh) Ｋｉｆ１８ａ抑制劑治療非小細胞肺癌的用途